Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust

 
back
8 Malignant disease and immunosuppression
08-01-05 Other antineoplastic drugs

Aflibercept Zaltrap®
Formulary

Vials: 100mg/4ml, 40mg/1ml

Link  NICE TA 294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Link  NICE TA 305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Link  NICE TA 307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Link  NICE TA 346: Aflibercept for treating diabetic macular oedema
Link  NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Link  NICE TA 486: Aflibercept for treating choroidal neovascularisation
 

Cytotoxic Drug  Red View adult BNF  View SPC online  HCD  CDF
Atezolizumab
Formulary

Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed

Also available through patient access scheme for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA 492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA 520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA 525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Link  NICE TA 638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Link  NICE TA 639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Link  NICE TA 666:Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
 

Red View adult BNF  View SPC online  CDF
Autologous Anti-CD19- Transduced CD3+ Cells Tecartus®
Formulary

Infusion: Bag containing 68 mL cell dispesion

 

Available through an approved pathway via one of the UK ten providers

Link  NICE TA 677: Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma
 

Red  View SPC online  CDF
Avelumab  Bavencio®
Formulary

20mg/ml concentrate for infusion.

Link  NICE TA 517: Avelumab for treating metastatic Merkel cell carcinoma
Link  NICE TA 645: Avelumab with axitinib for untreated advanced renal cell carcinoma
 

Red View adult BNF  View SPC online  HCD  CDF
Axicabtagene ciloleucel
Formulary
Link  NICE TA 559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies
 

Red View adult BNF  View SPC online  HCD  CDF
Axitinib
Formulary

Film coated tablets: 1mg, 3mg, 5mg and 7mg

Link  NICE TA 333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
 

Red View adult BNF  View SPC online  HCD
Bosutinib
Formulary

Film coated tablets: 100mg, 500mg

Link  NICE TA 401: Bosutinib for previously treated chronic myeloid leukaemia
 

Red View adult BNF  View SPC online  HCD  CDF
Carfilzomib Kyrolis®
Formulary

Vial: powder for infusion 10 mg, 30 mg and 60 mg

Link  NICE TA 657: Carfilzomib for previously treated multiple myeloma
 

Red View adult BNF  View SPC online  HCD
Ceritinib
Formulary

Capsule: 150mg

Link  NICE TA 395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA 500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
 

Red View adult BNF  View SPC online  HCD
Dabrafenib Tafinlar®
Formulary

Capsules: 50mg and 75mg

  • Approved for the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in line with NICE
  • Link  NICE TA 321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
    Link  NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
    Link  NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
     

    Red View adult BNF  View SPC online  HCD  CDF
    Daratumumab Darzalex®
    Formulary

    20mg/ml concentrate for infusion

    Link  NICE TA 510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
    Link  NICE TA 573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
     

    Red View adult BNF  View SPC online  HCD  CDF
    Encorafenib Braftovi®
    Formulary

    Capsules: 50 mg and 75 mg

    Link  NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
    Link  NICE TA 668:Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
     

    Red View adult BNF  View SPC online  HCD
    Entrectinib
    Formulary

    Capsules: 100mg and 200mg

    Link  NICE TA 643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
    Link  NICE TA 644: Entrectinib for treating NTRK fusion-positive solid tumours
     

    Red View adult BNF  View SPC online  CDF
    Eribulin Halaven®
    Formulary

    Vial: 0.88mg/2ml
    Vial: 1.32mg/3ml

    Link  NICE TA 423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
     

    Cytotoxic Drug  Red View adult BNF  View SPC online  HCD  CDF
    Gemtuzumab ozogamicin Mylotarg®
    Formulary
  • Approved for untreated acute myeloid leukaemia in line with NICE
  • Link  NICE TA 545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
     

    Red View adult BNF  View SPC online
    Gilteritinib (as fumarate)
    Formulary

    Tablets: 40mg

    Link  NICE TA 642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
     

    View adult BNF  View SPC online  HCD
    Ibrutinib Imbruvica®
    Formulary

    Capsules: 140mg

    Link  NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
    Link  NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
     

    Red View adult BNF  View SPC online  HCD  CDF
    Idelalisib
    Formulary

    Film coated tablets: 100mg, 150mg

    Link  NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia
     

    Red View adult BNF  View SPC online  CDF
    Inotuzumab ozogamicin Besponsa®
    Formulary
  • Approved for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults in line with NICE
  • Link  NICE TA 541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
     

    Red View adult BNF  View SPC online  HCD
    Ixazomib Ninlaro®
    Formulary

    Capsules: 4mg

    Link  NICE TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
     

    Red View adult BNF  View SPC online
    Lenvatinib Lenvima®
    Formulary

    Capsules: 4mg and 10mg

    Link  NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
    Link  NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
    Link  NICE TA 551: Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma
     

    Cytotoxic Drug  Red View adult BNF  View SPC online
    Midostaurin Rydapt®
    Formulary
    25mg capsules
    Link  NICE TA 522 Midostaurin for untreated acute myeloid leukaemia
     

    Cytotoxic Drug  Red View adult BNF  View SPC online
    Niraparib Zejula®
    Formulary
    Niraparib tosylate monohydrate 100mg capsules
    Link  NICE TA 528: Niraparib for maintenance treatment of relapsed, platinum sensitive ovarian, fallopian tube and peritoneal cancer
    Link  NICE TA 673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
     

    Cytotoxic Drug  Red View adult BNF  View SPC online  CDF
    Olaparib
    Formulary

    Capsules: 50mg

    - Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for olaparib are followed

    - approved for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer in line with NICE

    Link  NICE TA 598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
    Link  NICE TA 620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
     

    Red View adult BNF  View SPC online  CDF
    Olaratumab
    Formulary

    Concentrate for solution for infusion: 10 mg/mL


    Red View adult BNF  View SPC online
    Osimertinib
    Formulary

    Tablet: 40mg and 80mg

    Link  NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
    Link  NICE TA 654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
     

    Red View adult BNF  View SPC online  HCD
    Pablociclib Ibrance®
    Formulary

    Recommended for use according to NICE criteria

    Link  NICE TA 619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
     

    Red View adult BNF  View SPC online  CDF
    Panobinostat Farydak®
    Formulary

    Hard capsules: 10mg, 15mg, 20mg

    Link  NICE TA 380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
     

    Red View adult BNF  View SPC online
    Pembrolizumab Keytruda®
    Formulary

    Concentrate for infusion: 100 mg/4 mL

    See below for NICE approved indications

    Link  NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
    Link  NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
    Link  NICE TA 428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
    Link  NICE TA 519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
    Link  NICE TA 522 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer where cisplatin is unsuitable
    Link  NICE TA 531: Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer
    Link  NICE TA 540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
    Link  NICE TA 553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
    Link  NICE TA 557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
    Link  NICE TA 600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
    Link  NICE TA 661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
     

    Red View adult BNF  View SPC online  CDF
    Polatuzumab vedotin
    Formulary

    Vial: 30mg and 150mg, powder for concentrate for solution for infusion.

    Link  NICE TA 649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
     

    Red View adult BNF  View SPC online  HCD
    Ponatinib Iclusig®
    Formulary

    Tablets: 15mg, 45mg

    Link  NICE TA 451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
     

    Red View adult BNF  View SPC online  HCD  CDF
    Radium-223 dichloride
    Formulary
    Link  NICE TA 412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
     

    Red View adult BNF  View SPC online
    Rucaparib
    Formulary

    Film coated tablets: 200mg, 250mg, 300mg

    Link  NICE TA 611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
     

    Red View adult BNF  View SPC online  CDF
    Ruxolitinib
    Formulary

    Tablets: 5mg, 15mg, 20mg

    Link  NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
     

    Red View adult BNF  View SPC online  HCD  CDF
    Talimogene laherparepvec Imlygic®
    Formulary

    Solution for injection: 106 plaque forming units/1ml & 108 plaque forming units/1ml


    -approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy

    Link  NICE TA 410: Talimogene laherparepvec for treating unresectable metastatic melanoma
     

    Red View adult BNF  View SPC online
    Tisagenlecleucel Kymriah®
    Formulary
  • Indicated for treating 'paediatric and young adult patients up to 25 years of age with B‑cell acute lymphoblastic leukaemia that is refractory, in relapse post‑transplant or in second or later relapse as per NICE

  • NICE has recommended tisagenlecleucel for use within the Cancer Drugs Fund for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies.
  • Link  NICE TA 554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
    Link  NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
     

    Red View adult BNF  View SPC online  HCD  CDF
    Tivozanib Fotivda®
    Formulary

    Capsules: 890 mg and 1340 mg

     

    Link  NICE TA 512: Tivozanib for treating advanced renal cell carcinoma
     

    Red View adult BNF  View SPC online
    Trametinib Mekinist®
    Formulary

    Film coated tablets: 500microgram, 2mg

    Link  NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
     

    Red View adult BNF  View SPC online
    Ixazomib Ninlaro®
    Non Formulary

    View adult BNF  View SPC online
    Necitumumab
    Non Formulary

    View adult BNF  View SPC online  HCD
    Panitumumab Vectibix®
    Non Formulary

    Cytotoxic Drug  View adult BNF  View SPC online  HCD  CDF
    Sonidegib Odomzo®
    Non Formulary

    View adult BNF  View SPC online
    Vosaroxin Qinprezo
    Non Formulary

    View adult BNF  View SPC online  HCD